MartinJEdelmanMD

PubMed

• 132 citations
  Lung cancer in women: emerging differences in epidemiology, biology, and therapy.
  Leno Thomas, L. Austin Doyle, Martin J. Edelman
  Chest. 2005-07-01
• 34 citations
  Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy
  Steven H. Lin, Thomas J. George, Edgar Ben-Josef, Jeffrey D. Bradley, Kevin S. Choe
  Journal of the National Cancer Institute. 2013-05-15
• 346 citations
  2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
  Johan Vansteenkiste, L. Crinò, Christophe Dooms, Jean-Yves Douillard, Corinne Faivre-Finn
  Annals of Oncology. 2014-08-01

Journal Articles

• Lymph Node Size Predicts for Asymptomatic Brain Metastases in Non-Small Cell Lung Cancer Patients at Diagnosis  
  Martin J Edelman, Josephine Feliciano, Clinical Lung Cancer
• Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings:...  
  Bhatnagar  B, Gilmore  S, Goloubeva  O, Pelser  C, Medeiros  M, Chumsri  S, Tkaczuk  K, Edelman M, Bao  T, SpringerPlus, 1/1/2014
• RTOG 02-29: A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and Full Dose Radiotherapy Followed by Surgical Resection and Consolidative Therapy fo...  
  Suntharalingam M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, Yom S, Choy H, International Journal of Radiation Oncology, Biology, Physics, 10/1/2012
• Multicenter Trial of EC145 in Advanced, Folate Receptor Positive Adenocarcinoma of the Lung  
  Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB, J Thoracic Oncol, 10/1/2012
• A phase 1 study of folate conjugate EC145 in patients with refractory solid tumors  
  LoRusso PM, Edelman MJ, Bever SL, Forman KM, Pilat M, Quinn MF, Li J, Heath EI, Malburg LM, Patrick Klein J, Messmann RA, and Sausville E, J Clin Oncol, 10/1/2012
• Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: C...  
  Janne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, Vokes EE, Miller VA, J Clin Oncol, 6/10/2012
• EC145 in Lung Cancer  
  Edelman MJ, Pribble PB, Expert Opinion on Investigational Drugs, 5/1/2012
• CYFRA 21-1 as a prognostic and predictive marker in advanced non-small cell lung cancer : CALGB 150304  
  Edelman MJ, Hodgson L, Rosenblatt PY, Christenson RH, Wang X-F, Vokes E, Kratzke R, Journal of Thoracic Oncology, 4/1/2012
• A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California...  
  Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR, J Thorac Oncol, 3/1/2012
•  
  Edelman MJ and Shvartsbeyn M, Clin Lung Cancer, 1/1/2012
• Maintenance Therapy: A Skeptics View  
  Edelman MJ, Soria J-C, LeChevalier T, J Thoracic Oncol, 1/1/2012
• HCDC25A-Q110del: A Novel Cell Division Cycle 25A Isoform Aberrantly Expressed in Non-Small cell Lung Cancer  
  Younis RH, Cao W, Lin R, Xia R, Liu Z, Edelman MJ, Mei Y, Mao L, Ren, PLoS One, 1/1/2012
• Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotin...  
  Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H; MetLung Phase III Study Group, Clin Lung Cancer, 1/1/2012
• A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs paclitaxel plus carboplatin ...  
  Ansari RH, Socinski MA, Edelman MJ, Belani CP, Gonin R, Catalano RB, Marinucci DM, Comis RL, Obasaju CK, Chen R, Monberg MJ, Treat J; for the Alpha Oncology Research N..., Crit Rev Oncol Hematol, 5/1/2011
• Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-Small Cell Lung Cancer  
  Edelman MJ, Otterson G, Leach J, Malpass T, Salgia R, Jones D, Szakacs, Govindan R, J. Thor Oncol, 4/1/2011
• Treatment and survival in unresectable locally advanced NSCLC in the elderly: Analysis of the SEER Database  
  Davidoff A, Tang M, Seal B, Edelman MJ, J Thor Oncol, 1/1/2011
• Serum VEGF and COX-2/5LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304  
  Edelman, MJ, Hodgson L, Wang X-F, Christenson R, Vokes E, Kratzke R, J. Thor Oncol, 1/1/2011
• Apricoxib  
  Edelman MJ, Drugs of the Future, 1/1/2011
• Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003)  
  Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN Jr, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR, J Thorac Oncol, 1/1/2011
• A novel, broad-spectrum anticancer compound containing the imidazo(4,5-e)(1,3)diazepine ring system  
  Xie M, Ujjinamatada RK, Sadowska M, Lapidus RG, Edelman MJ, Hosmane RS, Bioorg Med Chem Lett, 8/1/2010
• Phase I Trial of Carboplatin/Paclitaxel/Bortezomib and Concurrent Radiotherapy Followed by Surgical Resection in Stage III Non-Small Cell Lung Cancer  
  Edelman MJ, Burrows W, Krasna MJ, Suntharalingam M, Lung Cancer, 1/1/2010
• Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation  
  Krasna MJ, Gamliel Z, Burrows WM, Sonett JR, Kwong KF, Edelman MJ, Hausner PF, Doyle LA, DeYoung C, Suntharalingam M, Ann Thorac Surg, 1/1/2010
• A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus p...  
  Treat J, Edelman MJ, Belani CP, Socinski MA, Monberg MJ, Chen R, Obasaju CK; for the Alpha Oncology Research Network, Lung Cancer, 1/1/2010
• Outcomes Associated with Brain Metastases in a Three-Arm Phase III Trial of Gemcitabine-Containing Regimens Versus Paclitaxel Plus Carboplatin for Advanced Non-small C...  
  Edelman MJ, Belani CP, Socinski MA, Ansari RH, Obasaju CK, Chen R, Monberg MJ, Treat J, J Thor Oncol, 1/1/2010
• Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non-Small-Cell Lung Cancer  
  Davidoff AJ, Tang M, Seal B, Edelman MJ, J Clin Oncol, 1/1/2010
• Join now to see all

Books/Book Chapters

• Am Soc Clin Oncol Educ Book 
  Chapter: 50 Years of progress in the systemic therapy of non-small cell lung cancer. 
  Wakelee H, Kelly K, Edelman MJ2014
• Advances in Radiation Oncology in Lung Cancer 
  Chapter: "Novel Targeted Agents and Radiopharmaceuticals in Lung Cancer" 
  Page 773 - 792Edelman MJ, Ijaz NEditors: B Jeremic.Springer-Verlag2011
• Encyclopedia of Respiratory Medicine 
  Chapter: "Chemotherapeutic Agents" 
  Page 332 - 339Edelman MJ and RupardEEditors: GJ Laurent and SD Shapiro.Elsevier Ltd.2006
• DeVita, Hellman and Rosenberg's Cancer Principles & Practice of Oncology Review 
  Chapter: "Epidemiology of Cancer" 
  Page 55 - 60Edelman MJEditors: R. Govindan.Lippincott, Williams and Wilkins Co.2005
• Conn's Current Therapy 
  Chapter: "Primary Lung Cancer" 
  Lara P, Edelman MJ, Gandara DRWB Saunders Co.2003
• Manual of Clinical Oncology 
  Chapter: "Lung Cancer" 
  Page 151 - 171Edelman MJ, Gandara DRWilliams and Wilkins Co.2000
• Conn's Current Therapy 
  Chapter: Nausea and Vomiting. 
  Edelman MJ, Lum DR, Gandara DRWB Saunders Co.1999
• ASCO Educational Book 
  Chapter: Current Status and Novel Therapeutic Approaches in Advanced Non-Small Cell Lung Cancer. 
  Gandara DR, Edelman MJ, Lara P, Lau D1999
• Join now to see all

Abstracts/Posters

• Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Al...
  Edelman MJ, Wang X-F,Hodgson L, Cheney RT, Baggstrom M, Sachdev T, Gajra A, Bertino E, Reckamp K, Molina J, Schiller J, Mitchell-Richards K, Friedman P, Ritter J, Vokes E, Proceedings AACR, 1/1/2014
• A Phase I Dose Escalation Trial of MAGE-A3 and HPV-16 Specific Peptide Immunomodulatory Vaccines in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the H...
  Zandberg D, Rollins S, Morales R, Taylor R, Wolf J, Cullen K, Ord R, Lubeck F, Papadimetriou JC, Mann D, Strome S, Edelman MJ, Proceedings ASCO, 1/1/2014
• Onartuzumab + erlotinib versus erlotinib in previously treated Stage IIIb or IV NSCLC: results from the pivotal Phase III randomized multi-center, placebo controlled M...
  Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Shames DS, Yu W, Paton VE, Mok TS, Proceedings ASCO, 1/1/2014
• Baseline Urinary PGE-M Is A Prognostic And Predictive Marker For Cox-2 Inhibition In Addition To Standard Chemotherapy For Advanced Non-small Cell Lung Cancer (nsclc):...
  Edelman MJ, Wang XF, Hodgson L,Milne GL, Cheney R, Baggstrom M, Sachdev T, Gajra A, Bertino E, Reckamp K, Molina J, Schiller J, Mitchell-Richards K, Friedman P, Ritter..., Int J Rad Biol Physics, 1/1/2014
• A randomized, open-label phase 2 study of single-agent vintafolide versus vintafolide + docetaxel versus docetaxel alone in second line NSCLC patients with all target ...
  Edelman MJ, Ma H, Perez W, Adjei AA, Hanna N, Proc ASCO, 1/1/2013
• RTOG 0618:  stereotactic body radiation therapy (SBRT) to treat operable early stage lung cancer patients.
  Timmerman R, Paulus R, Pass HI, Gore E, Edelman MJ, Galvin JM, Choy H, Straube W, Nedzi LA, McGarry R, Robinson CG, Schiff P, Bradley JD, Proc ASCO, 1/1/2013
• An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B (CALGB (Alliance)) trial 30406 in...
  Stinchcombe T, Sholl LM, Wang XF, Gu L, Socinski MA, Rodig SJ, Capelletti M, Crawford J, Edelman MJ, Villalona-Calero MA, Kratzke RA, Vokes EE, Miller VA, Janne PA, Proc ASCO, 1/1/2013
• Phase I and pharmacokinetic trial of the antitelomerase agent  KML001 (KML) and cisplatin (CDDP) in advanced solid tumors.
  Edelman MJ, Feliciano JL, Styblo M, Liu T, Lapidus RG, Saunders J, Gobburu J, Proc ASCO, 1/1/2013
• Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patient in the neoadjuvant/adjuvant settings: a single-center experience.
  BhatnagarB., Gilmore S, Goloubeva O, Wang L, Medeiros M, Chumsri S, Tkaczuk K, , Edelman MJ, Bao T, Proc ASCO, 1/1/2013
• The prevalence of MET expression by immunohistochemistry (IHC) in the MET Lung (OAM4971g) trial: a randomized, placebo-controlled Phase III study with erlotinib + plac...
  Edelman MJ, Spigel DR, O'Bryne K, Mok T, Yu W, Paton VE, Pas-Ares L, 14th World Conference on Lung Cancer, Sydney, Australia, 1/1/2013
• Case Series Report: EGFR Mutations in Small Cell Lung Carcinoma.
  Siegele BJ, Shilo K, Chao B, Edelman M, Carbone D, Zhao W, Ross P,Ioffe O Franklin WA, Aisner DL, AMP, 1/1/2013
• Co-development of a folate receptor targeted drug conjugate (EC145) and a folate receptor targeted imaging agent (EC20) in the treatment of advanced adenocarcinoma NSCLC.
  Edelman MJ, Bonomi P, Harb W, Pal S, Boccia R, Kraut M, Rogers J, Morgenstern D, Conley B, Garon E, European Lung Cancer Conference, Geneva, Switzerland, 4/1/2012
• A randomized, double-blind, placebo-controlled multicenter phase 2 study of the COX-2 inhibitor apricoxib (A) in combination with either docetaxel (doc) or pemetrexed ...
  Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson GA, Sequist LV, T Evans TL, Schneider BJ, Keresztes R, Rogers JS, Antunez de Mayolo J, Medeiros M, Zaknoen SL, Proc ASCO, 1/1/2012
• Socio-demographic and patient disparities in the use of first-line chemotherapy in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): Analysis of...
  Feliciano J, Gardner L, Edelman MJ, Davidoff A, Proc ASCO, 1/1/2012
• A phase I first in humans dose escalation trial of the polymer conjugate XMT-1001 in patients with advanced solid tumors.
  Sausville EA, Garbo LE, Weiss G, Edelman M, Fram RJ, Blank B, Shkolny D, Ramanathan R , Yurkovetskiy AV, Proc ASCO, 1/1/2012
• The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) + erlotinib versus placebo + erlotinib in patients with advanced, Met-positive n...
  Spigel DR, Edelman MJ, Mok T , O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H, Proc ASCO, 1/1/2012
• Outcome of advanced NSCLC patients with EGFR exon 19 and 21 mutations treated with erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in CALGB 30406.
  Janne PA, Wang X, Socinski MA, Crawford J, Gu L, Capelletti M, Edelman M, Villona-Calero R, Kratzke R, Vokes E, Miller VA, World Conference on Lung Cancer, 1/1/2011
• RTOG 0229:A Phase II Trial of Concurrent Chemotherapy and Full Dose Radiotherapy Followed by Surgical Resection and Consolidative Therapy For Locally Advanced Non Smal...
  Edelman MJ, PaulusR M. Suntharalingam M, Krasna M, Burrows W, Gore EM, Yom SS, Choy H, World Conference on Lung Cancer, 1/1/2011
• Results of a phase 2 study of ixabepilone plus carboplatin or paclitaxel plus carboplatin in first-line chemotherapy for non-small cell lung cancer (NSCLC) overexpress...
  Edelman MJ, Schneider C-P, Tsai C-M, Kim H-T, Quoix E, Luft A, Kaleta R, Mukhopadhyay J, Whitaker L, Reck M, IASLC Chicago Conference, 12/1/2010
• SCH 727965-A Novel Cyclin-Dependent Kinase Inhibitor-Updated Results from Phase I and Phase II Studies.
  Mita M, Edelman M, Mita A,Joy AA, Shapiro CL, Sankhala K, MoseleyJ, PoonJ, Statkevich P, YaoS-L, Warren S, Bannerji R, and Shapiro G, Chemotherapy Foundation, New York, NY, 11/1/2010
• Serum VEGF and COX-2/5LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304.
  Edelman MJ, Hodgson Lm, Wang X, Christenson R,JewellS, Vokes E, Kratzke R, Proc ASCO, 1/1/2010
• Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma:...
  Janne PA, Wang XF, Socinski MA, Crawford J, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke RA, Vokes EE, Miller VA, Proc ASCO, 1/1/2010
• A phase III prospective randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor, gefitinb in completely resected stage IB-...
  Goss GD, Lorimer I,. Tsao MS, O'Callaghan CJ, Ding K,. Masters GA, Gandara DR, Jett JR,Edelman MJ, Shepherd FA, Proc ASCO, 1/1/2010
• RTOG 0229: A phase II trial of neoadjuvant therapy with concurrent chemotherapy and high dose radiotherapy (XRT) Followed by resection and consolidative therapy for LA...
  Suntharalingam M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, Yom SS, Choy H, Proc ASCO, 1/1/2010
• Hurria A,Lichtman SM, Hussain A, Edelman MJ. Development of a performance status prediction model for use in administrative data analyses.
  Davidoff AJ, I. H. Zuckerman IH, N. B. Pandya NB, F. Hendrick F, X. Ke X, A, Proc ASCO, 1/1/2010
• Join now to see all

Lectures

• A two-part, open-label, randomized, phase 2/3 study of dinutuximab and irinotecan versus irinotecan for second-line treatment of subjects with relapsed or refractory s... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• "Targeted Therapies in Lung Cancer" 
  Gdansk, Poland - 8/30/2014
• Internal Medicine Grand Rounds: "Current Status of Treatment of Non-small Cell Lung Cancer." 
  University of New Mexico, Albuquerque, NM - 1/16/2014
• "Highlights of the Day-Medical Oncology" 
  Sydney, Australia - 10/29/2013
• Internal Medicine Grand Rounds: "Personalized Medicine, Targeted Therapies and Other Politically Correct Studies in Lung Cancer." 
  University of Maryland, Baltimore, MD - 7/6/2013
• "Biology of Squamous Cell Carcinoma." 
  Lugano, Switzerland - 5/9/2013
• "Tailoring Treatment Plans to Improve Outcomes in the Management of NSCLC" 
  Orlando, FL - 5/2/2013
• 17th Annual Perspectives In Thoracic Oncology 2012 
  Imedex, New York, New York - 11/18/2012
• "Mechanisms of Resistance to Anti-angiogenic Agents" 
  Dresden, Germany - 9/13/2012
• "EC145: Early Clinical Results." 
  Dresden, Germany - 9/13/2012
• "KML001: An Anti-telomerase Agent" 
  Seoul, South Korea - 9/5/2012
• Grand Rounds: "Prevention, Screening and Treatment of Non-small Cell Lung Cancer." 
  University of Maryland Department of Family Practice, Baltimore, MD - 8/19/2012
• "ASCO Update." 
  Baltimore, MD - 6/12/2012
• "Discussant" 
  Amsterdam, Netherlands - 7/4/2011
• "New Questions for Old (and not so old) Drugs: the Elderly and Maintenance" 
  Chicago, IL - 6/5/2011
• Plenary Discussion: "Lung Cancer: The End of the Beginning" 
  Chicago, IL - 6/6/2010
• "Management of Localized Lung Cancer" 
  San Diego, CA - 2/16/2010
• "Medical Management of Brain Metastases in Non-small Cell Lung Cancer." 
  Dublin, Ireland - 1/27/2010
• "Multidisciplinary Treatment of Locally Advanced Non-small Cell Lung Cancer." 
  Beijing, PRC - 10/22/2009
• "COX-2 as a Therapeutic Target for Lung Cancer." 
  Denver, CO - 4/21/2009
• "Anti-telomere and Telomerase Agents in Non-Small Cell Lung Cancer" 
  St. Paul De Vence, France - 4/3/2009
• "Epothilones and other Anti-mitotic Agents in Non-Small Cell Lung Cancer." 
  Santa Monica, CA - 2/25/2009
• "Beyond Bevacizumab: New Anti-angiogenic and Anti Vascular Agents" 
  New York, NY - 11/22/2008
• "Treatment of Non-small Cell Lung Cancer in Elderly and PS-2 Patients" 
  Omaha, NE - 11/3/2008
• "The Role of Chemotherapy in the Multimodality Management of Non-Small Cell Lung Cancer." 
  Boston, MA - 9/21/2008
• Join now to see all

Other

• Lung Cancer Case Studies. 
  Gandara DR, Edelman MJ, Marelich G
  http://www.vlh.com
• Integration of New Chemotherapeutic Agents Into Combined Modality Therapy of Stage III Non-Small Cell Lung Cancer. 
  Gandara DR, Edelman MJ, Lau D, Roach M, Proc Current Approaches Rad Oncol, Biol, Physics
  1/1/1995
• Promising New Agents in the Treatment of Lung Cancer: Potential for Combined Modality Therapy. 
  Gandara DR, Edelman MJ, Proc Current Approaches Rad Oncol, Biol, Physics
  1/1/1993
• Cytokines in the Pathogenesis of the Cancer Cachexia Syndrome Biotherapy for Solid Tumors. 
  Edelman MJ, Gandara DR, UC Davis Symposium
  1/1/1993
• Join now to see all